Skip to content
★ Sign in to follow
HJ

Howard J. Leonhardt

U.S. Stem Cell, Inc.
Total declarations
6
Company
1
▲ Purchases (6 ops.)
€665k
▼ Sales (0 ops.)
—

Latest filing published 01 Sept 2009 for U.S. Stem Cell, Inc., €33k.

Insider track record

Disclosed buys
6
Disclosed sells
0
Signal history

No signal scores available.

Closed purchases

Market purchases
6
Positive at T+90
50%
Median T+90
-2.4%

Based on 6 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.

Purchases by company

Since each purchase

  • Filed 01 Sept 2009 · 6278 days ago · €33k
    -74.4%
    Entry US$780.00 · Close at T+365 US$200.00
  • Filed 27 May 2009 · 6375 days ago · €65k
    -48.8%
    Entry US$840.00 · Close at T+365 US$430.00
  • Filed 21 Feb 2008 · 6836 days ago · €406k
    -79.2%
    Entry US$4,530.00 · Close at T+365 US$940.00

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Howard J. Leonhardt: trading record in brief

This profile gathers the share dealings of Howard J. Leonhardt in U.S. Stem Cell, Inc. The record holds 6 filings, for trades running from 19 February 2008 to 11 June 2009.

Every open-market trade on record is a purchase: 6 purchases worth €665k, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Since January 2009: 4 purchases and no sales on the market.

A typical purchase (the median) is worth €49k. For 6 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 50% of cases, with a median move of -2.4%. Past outcomes like these are no guarantee of what comes next.

The newest entry dates from 1 September 2009: an open-market purchase of €33k, in U.S. Stem Cell, Inc. The median gap between a trade and its publication by SEC (Form 4) is 48 days. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.

Companies and markets linked to Howard J. Leonhardt

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations6 total
  • ▲
    Chairman, CEO & CTOExecutivesU.S. Stem Cell, Inc.
    47,003 USD0SEC
    62,670 shares@ US$0.75Common StockSEC:0001388431-09-000021:0
    Canonical exit: 27 Aug 2009 (T+90)
  • ▲
    Chairman, CEO & CTOExecutivesU.S. Stem Cell, Inc.
    31,998 USD0SEC
    43,240 shares@ US$0.74Common StockSEC:0001388431-09-000021:1
    Canonical exit: 2 Sept 2009 (T+90)
  • ▲
    Chairman, CEO & CTOExecutivesU.S. Stem Cell, Inc.
    46,001 USD0SEC
    64,790 shares@ US$0.71Common StockSEC:0001388431-09-000021:2
    Canonical exit: 9 Sept 2009 (T+90)
  • ▲
    Chairman, CEO & CTOExecutivesU.S. Stem Cell, Inc.
    87,999 USD0SEC
    129,410 shares@ US$0.68Common StockSEC:0001388431-09-000014:0
    Canonical exit: 12 Aug 2009 (T+90)
  • ▲
    Executive Chairman & CTOExecutivesU.S. Stem Cell, Inc.
    598,500 USD0SEC
    114,000 shares@ US$5.25Common StockSEC:0001144204-08-011190:0
    Canonical exit: 19 May 2008 (T+90)
  • ▲
    Executive Chairman & CTOExecutivesU.S. Stem Cell, Inc.
    154,011 USD0SEC
    30,000 shares@ US$5.1337Common StockSEC:0001144204-08-011190:1
    Canonical exit: 19 May 2008 (T+90)

6 of 6 declarations